Thursday, July 27, 2017, Baltimore, Md., Insilico Medicine (“Insilico”), a Baltimore-based leader in artificial intelligence (“AI”) for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited (“Juvenescence AI”). Juvenescence AI will develop the first compounds generated by Insilico’s deep-learned drug discovery engines, which train over structural, functional, and phenotypic data in order to predict the biological activity of compounds. Insilico’s platforms incorporate new AI techniques such as Generative Adversarial Networks in order to generate novel compounds with desired pharmacokinetic and pharmacodynamic properties.
The principals of Juvenescence, Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan, have extensive track records in drug development, company formation, and biotech investment. The Juvenescence executive and scientific team hopes to combine their classical drug development expertise, earned through careers in the pharmaceutical industry and through their successful early investments in companies such as Medivation and Biohaven Pharmaceuticals (NYSE:BHVN), to bear on the new prospects presented by AI-assisted drug development. The team believes that advances in AI provide new avenues for clinical, regulatory and commercial success.
Juvenescence AI has agreed to license selected novel and repurposed compound families from Insilico on an ongoing basis, with the aim of developing therapies for both ageing itself and the diseases of ageing, such as diabetes, dementia, cancer, respiratory disease and cardiovascular disease, which increasingly burden our health care systems as the world’s population continues to age.
“We are very pleased to partner with Alex Zhavoronkov and his team at Insilico Medicine. Artificial intelligence is set to increase efficiencies in many sectors, something sorely needed in drug development as evidenced by the prolonged decline in the sector’s productivity. Insilico Medicine’s approach has massive potential to reduce the cost associated with the discovery of new drugs,” said Juvenescence’s Chairman, Jim Mellon, adding, “We are excited by the potential for AI to streamline the longest and most costly portions of the drug development cycle: clinical trials. With Insilico Medicine’s help, we hope Juvenescence AI will both develop therapeutics that treat the diseases that plague all of us as we age and eventually treat the ageing process itself. ”
Insilico Medicine was the first company to apply deep generative adversarial networks (GANs) to generation of new molecular structures with specified parameters and published a seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016, demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors’ Choice Award.
The pharmaceutical industry has is expected to benefit from the recent advances in AI. Insilico Medicine was profiled in the recent article in Nature Biotechnology titled “AI-powered drug discovery captures pharma interest” among the other companies utilizing machine learning for drug discovery. The agreement with Juvenescence is expected to set a precedent for the new molecules discovered using the new generation of artificial intelligence by a team of expert drug developers.